Key result
In patients requiring both dual antiplatelet therapy and anticoagulation post-PCI, the shortest duration of triple therapy should be prescribed to minimize bleeding risk.
In post-PCI patients requiring anticoagulation, triple therapy increases bleeding risk and should be prescribed for the shortest duration possible.
In patients who have had percutaneous coronary intervention for acute coronary syndromes or stable angina dual antiplatelet therapy is required. If there is a history of atrial fibrillation, thrombosis or presence of a mechanical heart valve then long term anticoagulation may be necessary. However, the use of antiplatelets with anticoagulation increases the risk of bleeding. The need for anticoagulation in such patients needs to be carefully assessed by taking into account the risk of bleeding with anticoagulation and the risk of thromboembolic events without anticoagulation. If triple therapy is required then the shortest duration of treatment should be prescribed.
No takes yet. Share an insight, caveat, or question.
Shabnam Rashid (2016) conducted a review in post percutaneous coronary intervention for acute coronary syndromes or stable angina. Triple therapy (dual antiplatelet therapy and anticoagulation) was evaluated. In patients requiring both dual antiplatelet therapy and anticoagulation post-PCI, the shortest duration of triple therapy should be prescribed to minimize bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: